Enrolling

A Study of Baricitinib in Participants With Rheumatoid Arthritis (RA-BRANCH)

I4V-MC-JAJD -

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).

Enter your city or zip code to find the nearest site

See if You May Qualify

Answer a few questions to see if you meet key criteria for this study.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Rheumatoid Arthritis
What the trial is testing?
Baricitinib, TNF Inhibitor
Could I receive a Placebo?
No
Enrollment Goal
1300
Trial Dates
Feb 14, 2020 - Feb 2026
How long will I be in the trial?
Your participation in this trial could last up to 5 years.
Trial Phase
IV

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have at least one of the following characteristics: - Documented evidence of a VTE prior to this study - At least 60 years of age - A body mass index (BMI) greater than or equal to 30 kilograms per meter squared (kg/m²), or - Age 50 to less than 60 years and BMI 25 to less than 30 kg/m²

  • Participants must have an inadequate response or intolerance to at least 1 disease-modifying antirheumatic drugs (DMARD) (synthetic or biologic)

Participants Must Not:

  • Participant must not have prior use of a Janus kinase (JAK) inhibitor or have received more than 1 prior TNF inhibitor that was: - Discontinued for IR (lack or loss of efficacy) for RA, or - Discontinued for intolerance (AE) when used for any indication

  • Participants must not be pregnant or breastfeeding

  • Participants must not have had more than one VTE

  • Participants must not have cancer

  • Participants must not have active herpes zoster, serious infection, active tuberculosis, or any other serious illness

  • Participants must not have had a live vaccine within four weeks of study start

  • Participants must not have participated in any other clinical trial within four weeks of study start

  • Participants must not have a history of IV drug use, other illicit drug abuse, or chronic alcohol abuse in the past year

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources

Rheumatoid Arthritis Research

By volunteering to take part in Rheumatoid Arthritis clinical trials, you may be able to play an important role in the research and development of potential new treatments and medicines. We understand that when you or a loved one take part in a clinical trial, it is a big decision. It is important for you to understand why the research is being carried out and what taking part will mean for you. Learn more about Lilly

Rheumatoid Arthritis Research

Immunology  Research

Click the below button to learn more about our autoimmune disease research and clinical trials.

Learn More

Clinical Trial Participation: What to Expect

A clinical trial is a scientific study. It helps us learn if a new medicine or treatment works and how it works. Clinical trials can also be called clinical research studies. Learn more about clinical research studies and what to expect when taking part in a clinical trial.